Nonhuman leukocyte antigen antibodies that have impact in the heart transplant patientReddy, Yogesh N.V.a; Pereira, Naveen L.a,bCurrent Opinion in Organ Transplantation: June 2019 - Volume 24 - Issue 3 - p 279–285 doi: 10.1097/MOT.0000000000000642 HEART TRANSPLANTATION: Edited by Jon A. Kobashigawa Buy SDC Abstract Author InformationAuthors Article MetricsMetrics Purpose of review Despite human leukocyte antigen (HLA) matching and monitoring for donor-specific HLA antibodies, antibody-mediated rejection and chronic rejection in the form of allograft vasculopathy and chronic graft dysfunction continue to occur. There has been increasing interest in non-HLA antibodies as mediators of these changes. Recent findings In this review, we discuss the recent literature describing the importance of non-HLA antibodies in organ transplantation and summarize the literature evaluating such antibodies in heart transplantation. Summary Monitoring of non-HLA antibodies requires additional measurement standardization and correlation of specific antibodies with outcomes. However, there is promise that identification with newer immunoproteomic techniques and therapy toward such antibodies may improve long-term graft outcomes and decrease acute rejection and allograft vasculopathy. aThe Department of Cardiovascular Medicine bDepartment of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota, USA Correspondence to Naveen L. Pereira, MD, Mayo Clinic and Foundation, 200 First Street SW, Rochester, MN 55905, USA. Tel: +1 507 284 8260; e-mail: Pereira.email@example.com Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.